C.M. Bidwell & Associates’s AbbVie ABBV Stock Holding History

C.M. Bidwell & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77K	Hold	11	–	–	﹤0.01%	388
2026 Q1	$2.39K	Hold	11	–	–	﹤0.01%	391
2025 Q4	$2.51K	Hold	11	–	–	﹤0.01%	378
2025 Q3	$2.55K	Buy	+11	New	+$2.24K	﹤0.01%	384
2025 Q2	–	Sell	-813	Closed	-$170K	–	447
2025 Q1	$170K	Hold	813	–	–	0.1%	134
2024 Q4	$144K	Buy	+813	New	+$149K	0.09%	149
2021 Q3	–	Sell	-1,088	Closed	-$123K	–	560
2021 Q2	$123K	Buy	1,088 +25	+2%	+$2.82K	0.08%	232
2021 Q1	$115K	Buy	1,063 +41	+4%	+$4.38K	0.08%	227
2020 Q4	$110K	Sell	1,022 -241	-19%	-$23.2K	0.09%	214
2020 Q3	$111K	Sell	1,263 -222	-15%	-$20.9K	0.1%	192
2020 Q2	$146K	Sell	1,485 -40	-3%	-$3.52K	0.13%	162
2020 Q1	$116K	Buy	+1,525	New	+$130K	0.12%	155
2018 Q3	–	Sell	-2,635	Closed	-$244K	–	381
2018 Q2	$244K	Sell	2,635 -2,525	-49%	-$247K	0.23%	123
2018 Q1	$488K	Buy	5,160 +1,215	+31%	+$133K	0.45%	59
2017 Q4	$382K	Buy	+3,945	New	+$372K	0.33%	89
2015 Q3	–	Sell	-4,805	Closed	-$323K	–	222
2015 Q2	$323K	Buy	+4,805	New	+$314K	0.07%	127

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

C.M. Bidwell & Associates's ABBV Position: Q2 2026 in Review

C.M. Bidwell & Associates held its AbbVie (ABBV) position steady in Q2 2026 at 11 shares worth $2.77K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

C.M. Bidwell & Associates first reported a position in ABBV in Q2 2015 and has held it in 16 quarters since. The position peaked at $488K in Q1 2018. 4,220 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

C.M. Bidwell & Associates held 11 shares of AbbVie worth $2.77K as of Q2 2026.
C.M. Bidwell & Associates left its AbbVie share count unchanged in Q2 2026.
AbbVie made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #388 holding.
C.M. Bidwell & Associates first reported a position in AbbVie in Q2 2015 and has held it in 16 quarters since.
C.M. Bidwell & Associates's AbbVie position peaked at $488K in Q1 2018.
4,220 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.